BCP
NVAX icon

Berylson Capital Partners’s Novavax NVAX Stock Holding History

Berylson Capital Partners’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-30,104
Closed -$3.36M – 77
2020
Q4 		$3.36M Hold
30,104
– – 0.57% 55
2020
Q3 		$3.26M Buy
+30,104
New +$3.67M 1.14% 34

Other funds holding NVAX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Berylson Capital Partners's NVAX Position: Q1 2021 in Review

Berylson Capital Partners sold out of Novavax (NVAX) in Q1 2021, closing a stake of 30,104 shares — an estimated $3.36M sold.

Berylson Capital Partners first reported a position in NVAX in Q3 2020 and held it in 2 quarters. The position peaked at $3.36M in Q4 2020. 389 funds tracked by Wall St. Rank hold NVAX as of Q1 2021.

  • Berylson Capital Partners reported no remaining Novavax position as of Q1 2021 after selling out during the quarter.
  • Berylson Capital Partners sold 30,104 Novavax shares in Q1 2021, an estimated $3.36M.
  • Berylson Capital Partners first reported a position in Novavax in Q3 2020 and held it in 2 quarters.
  • Berylson Capital Partners's Novavax position peaked at $3.36M in Q4 2020.
  • 389 funds tracked by Wall St. Rank held Novavax as of Q1 2021.

Based on Berylson Capital Partners's 13F filing for Q1 2021, filed 17 May 2021.